NL-OMON50069已完成3 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA - WA42380
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Age ><= 18 years
- •- Hospitalized with COVID-19 pneumonia confirmed per a positive PCR of any
- •specimen (e.g., respiratory, blood, urine, stool, other bodily fluid) and
- •evidenced by chest X-ray or CT scan
- •- SpO2 <<= 93% or PaO2/FiO2 < 300 mmHg.
排除标准
- •- Known severe allergic reactions to TCZ or other monoclonal antibodies
- •- Active TB infection
- •- Suspected active bacterial, fungal, viral, or other infection (besides
- •COVID-19)
- •- In the opinion of the investigator, progression to death is imminent and
- •inevitable within the next 24 hours, irrespective of the provision of treatments
- •- Have received oral anti-rejection or immunomodulatory drugs (including
- •tocilizumab) within past 3 months
- •- Pregnant or lactating women
- •- Participating in other drug clinical trials (with possible exception of
- •anti-viral trials)
- •- ANC < 1000/mm3
研究者
相似试验
进行中（未招募）
不适用
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-ESF. Hoffmann-La Roche Ltd.180
进行中（未招募）
不适用
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-ITF. HOFFMANN - LA ROCHE LTD.180
进行中（未招募）
不适用
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-DEF. Hoffmann-La Roche Ltd.125
进行中（未招募）
1 期
STUDY OF ECULIZUMAB IN REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG)SUBJECTSGeneralized Myasthenia GravisEUCTR2013-003589-15-BEAlexion Pharmaceuticals, Inc.92
进行中（未招募）
不适用
STUDY OF ECULIZUMAB IN REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG)SUBJECTSMedDRA version: 18.0Level: HLTClassification code 10071942Term: Myasthenia gravis and related conditionsSystem Organ Class: 100000004859Generalized Myasthenia GravisEUCTR2013-003589-15-FRAlexion Pharmaceuticals, Inc.92